NCT03568058 2026-03-24
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Phase 1 Completed
Clinical Trials
189 trialsNCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02275910 2025-12-16
Phase 1 Study of E7090 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT04197713 2025-10-20
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03972150 2025-10-06
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02674152 2025-10-01
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02689505 2025-10-01
Weekly BI 836880 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT05237206 2025-09-18
Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies
Alloplex Biotherapeutics Inc
Phase 1 Completed
NCT04147234 2025-08-19
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT00716417 2025-08-05
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03307629 2025-07-29
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Noxopharm Limited
Phase 1 Completed
NCT01403974 2025-07-25
Phase I Trial of BI 836845 for Various Solid Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT01317420 2025-07-11
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Boehringer Ingelheim
Phase 1 Completed
NCT02145741 2025-06-19
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03724890 2025-04-10
Study of Avelumab-M3814 Combinations
EMD Serono
Phase 1 Completed
NCT01214616 2025-02-07
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03406871 2025-01-24
REGONIVO
National Cancer Center Hospital East
Phase 1 Completed
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT01870505 2024-12-09
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03027128 2024-11-20
QUILT-3.028: Study of haNKā¢ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed
NCT02265536 2024-10-28
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04472650 2024-10-26
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
BeiGene
Phase 1 Completed
NCT04138823 2024-10-09
A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
Phase 1 Completed
NCT03447314 2024-09-23
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01346358 2024-09-19
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT03329001 2024-07-25
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
Tesaro, Inc.
Phase 1 Completed
NCT00543387 2024-06-05
MK-5108-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02517398 2024-05-03
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
EMD Serono
Phase 1 Completed
NCT04349280 2024-04-18
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT02516553 2024-04-15
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
Boehringer Ingelheim
Phase 1 Completed
NCT03604445 2024-03-04
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
Boehringer Ingelheim
Phase 1 Terminated
NCT02564900 2024-01-22
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT03383692 2023-12-11
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT04147247 2023-11-29
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
Boehringer Ingelheim
Phase 1 Completed
NCT04635631 2023-10-10
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
Pfizer
Phase 1 Completed
NCT02273388 2023-10-03
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01772563 2023-09-01
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT04116710 2023-08-23
A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors
Heat Biologics
Phase 1 Completed
NCT03745989 2023-07-27
MK-8353-014
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01268293 2023-06-22
A Study of E7080 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT02583269 2023-06-05
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Wake Forest University Health Sciences
Phase 1 Completed
NCT02761694 2023-05-06
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT02688088 2022-10-18
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Eli Lilly and Company
Phase 1 Completed
NCT02937116 2022-10-14
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT00199836 2022-10-10
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and MontanideĀ® ISA-51 in Patients With Cancer.
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00291447 2022-10-10
111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00293215 2022-10-10
Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT00299728 2022-10-10
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Ludwig Institute for Cancer Research
Phase 1 Completed